Alpine Global Management’s Passage Bio PASG Stock Holding History

Alpine Global Management’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-729	Closed	-$93K	–	644
2021 Q4	$93K	Buy	+729	New	+$119K	0.01%	669

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Alpine Global Management's PASG Position: Q1 2022 in Review

Alpine Global Management sold out of Passage Bio (PASG) in Q1 2022, closing a stake of 729 shares — an estimated $93K sold.

Alpine Global Management first reported a position in PASG in Q4 2021 and held it in 1 quarter. The position peaked at $93K in Q4 2021. 108 funds tracked by Wall St. Rank hold PASG as of Q1 2022.

Alpine Global Management reported no remaining Passage Bio position as of Q1 2022 after selling out during the quarter.
Alpine Global Management sold 729 Passage Bio shares in Q1 2022, an estimated $93K.
Alpine Global Management first reported a position in Passage Bio in Q4 2021 and held it in 1 quarter.
Alpine Global Management's Passage Bio position peaked at $93K in Q4 2021.
108 funds tracked by Wall St. Rank held Passage Bio as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.